Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionVRTIX - Vanguard Russell 2000 Index Fund Institutional Shares
Latest Disclosed Ownership573,537 shares
Latest Disclosed Value $ 13,237,233
VRTIX - Vanguard Russell 2000 Index Fund Institutional Shares reports 0.91% increase in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On April 28, 2026 - VRTIX - Vanguard Russell 2000 Index Fund Institutional Shares filed a NPORT-P form disclosing ownership of 573,537 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $13,237,234 USD as of February 28, 2026. The entity filed a previous NPORT-P on January 28, 2026 disclosing 568,371 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of 0.91% during the quarter. The current value of the position is $18,060,680 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-28 2026-02-28 NP CATALYST PHARMAC EC US14888U1016 573,537 5,166 0.91 13,237 -0.51 0.0872
2026-01-28 2025-11-30 NP CATALYST PHARMAC EC US14888U1016 568,371 26,144 4.82 13,306 19.18 0.0935
2025-10-28 2025-08-31 NP CATALYST PHARMAC EC US14888U1016 542,227 -24,982 -4.40 11,164 -21.14 0.0867
2025-07-29 2025-05-31 NP CATALYST PHARMAC EC US14888U1016 567,209 54,869 10.71 14,158 20.72 0.1147
2025-04-25 2025-02-28 NP CATALYST PHARMAC EC US14888U1016 512,340 -13,526 -2.57 11,727 1.05 0.0988
2025-01-27 2024-11-30 NP CATALYST PHARMAC EC US14888U1016 525,866 53,988 11.44 11,606 21.45 0.0845
2024-10-28 2024-08-31 NP CATALYST PHARMAC EC US14888U1016 471,878 52,893 12.62 9,556 41.05 0.0887
2024-07-26 2024-05-31 NP CATALYST PHARMAC EC US14888U1016 418,985 53,962 14.78 6,775 15.78 0.0693
2024-04-29 2024-02-29 NP CATALYST PHARMAC EC US14888U1016 365,023 55,627 17.98 5,851 31.07 0.0623
2024-01-29 2023-11-30 NP CATALYST PHARMAC EC US14888U1016 309,396 31,580 11.37 4,465 14.46 0.0639
2023-10-30 2023-08-31 NP CATALYST PHARMAC EC US14888U1016 277,816 16,533 6.33 3,901 29.27 0.0563
2023-07-31 2023-05-31 NP CATALYST PHARMAC EC US14888U1016 261,283 -1,898 -0.72 3,018 -24.88 0.0498
2023-04-28 2023-02-28 NP CATALYST PHARMAC EC US14888U1016 263,181 20,502 8.45 4,016 -1.30 0.0606
2023-01-27 2022-11-30 NP CATALYST PHARMAC EC US14888U1016 242,679 16,968 7.52 4,070 33.15 0.0657
2022-10-31 2022-08-31 NP CATALYST PHARMAC EC US14888U1016 225,711 -22,613 -9.11 3,056 71.01 0.0534
2022-08-01 2022-05-31 NP CATALYST PHARMAC EC US14888U1016 248,324 -14,649 -5.57 1,788 -12.87 0.0285
2022-04-29 2022-02-28 NP CATALYST PHARMAC EC US14888U1016 262,973 14,946 6.03 2,051 18.15 0.0280
2022-01-31 2021-11-30 NP CATALYST PHARMAC EC US14888U1016 248,027 25,495 11.46 1,736 41.60 0.0234
2021-10-29 2021-08-31 NP CATALYST PHARMAC EC US14888U1016 222,532 26,591 13.57 1,226 13.20 0.0179
2021-07-30 2021-05-31 NP CATALYST PHARMAC EC US14888U1016 195,941 14,520 8.00 1,084 53.62 0.0182
2021-04-29 2021-02-28 NP CATALYST PHARMAC EC US14888U1016 181,421 48,663 36.66 706 45.36 0.0138
2021-01-29 2020-11-30 NP CATALYST PHARMAC EC US14888U1016 132,758 10,835 8.89 486 21.55 0.0158
2020-10-29 2020-08-31 NP CATALYST PHARMAC EC US14888U1016 121,923 6,080 5.25 400 -20.04 0.0164
2020-07-30 2020-05-31 NP CATALYST PHARMAC EC US14888U1016 115,843 9,515 8.95 499 11.63 0.0240
2020-04-29 2020-02-29 NP Catalyst Pharmaceuticals EC US14888U1016 106,328 -6 -0.01 448 -9.33 0.0220
2020-01-29 2019-11-30 NP Catalyst Pharmaceuticals EC US14888U1016 106,334 106,334 493 0.0218
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.